Three Horizons Framework
for Manufacture of pharmaceuticals, medicinal chemical and botanical products (ISIC 2100)
The Three Horizons Framework is an excellent fit for the pharmaceutical industry due to its unique characteristics: extremely long R&D cycles (MD04), high capital investment (IN05), significant regulatory hurdles (IN04), and the critical impact of patent expiries (MD01). Companies must...
Strategic Overview
The Three Horizons Framework is a vital strategic tool for the "Manufacture of pharmaceuticals, medicinal chemical and botanical products" industry, which must constantly balance immediate commercial pressures with long-term innovation. Given the industry's extended R&D cycles (MD04), significant capital investments (IN05), and existential threat of patent cliffs (MD01), effectively managing innovation across different timeframes is paramount. This framework provides a structured approach to allocate resources and attention, ensuring that while current revenue streams (Horizon 1) are optimized and defended, future growth opportunities (Horizon 2) are nurtured, and disruptive, long-term innovations (Horizon 3) are explored.
Horizon 1 activities focus on maximizing existing drug portfolios through lifecycle management, indication expansion, and defending against generic competition, directly addressing 'Maintaining Revenue Growth Post-Patent Expiry' (MD01). Horizon 2 involves investing in mid-stage drug candidates, entering new therapeutic areas, or strategically acquiring assets to replenish the pipeline and build new capabilities. Horizon 3 is dedicated to exploring truly novel, potentially transformative technologies like gene therapy, precision medicine, or digital health platforms, which, while high-risk, promise significant future market disruption and leadership. This multi-horizon approach helps companies navigate the inherent uncertainties and high costs of pharmaceutical R&D (IN05) while ensuring sustained competitive advantage in a rapidly evolving market.
5 strategic insights for this industry
Patent Cliff Management is a Horizon 1 Imperative
For pharmaceutical companies, Horizon 1 is heavily focused on extending the commercial life of existing blockbuster drugs post-patent expiry (MD01). This involves strategies like developing new formulations, expanding indications, combination therapies, or optimizing manufacturing processes to reduce costs and maintain market share against generic competition. Failure to manage this horizon effectively can lead to significant revenue erosion.
Horizon 2: The Core Pipeline Replenishment Engine
Horizon 2 represents the critical mid-term growth engine, focusing on advancing drug candidates through late-stage clinical trials, strategic acquisitions of promising assets, and expanding into new therapeutic areas. This horizon balances the risk of early-stage discovery with the high investment required for clinical development (MD04), ensuring a steady stream of future revenue, directly addressing 'High R&D Investment for New Products' (MD01).
Horizon 3 Requires Patient Capital and Ecosystem Engagement
Investing in Horizon 3 innovations (e.g., gene therapy, precision medicine, digital therapeutics, regenerative medicine) demands patient capital, tolerance for high risk, and often external partnerships or venture models. These initiatives are aimed at creating entirely new markets or business models (MD08) and addressing unmet medical needs, but come with 'High Financial Risk & Capital Intensive' (IN05) and 'Rapidly Evolving IP Landscape' (IN03) challenges.
Balancing Resource Allocation Across Horizons is Challenging
A significant challenge is allocating sufficient resources (financial, human, strategic attention) across the three horizons, especially given the immediate pressures of Horizon 1 and the long-term, uncertain nature of Horizon 3. Over-emphasis on H1 can stifle future growth, while neglecting H1 can lead to immediate financial instability. This impacts 'R&D Burden & Innovation Tax' (IN05) and 'Managing High R&D Risk and Uncertainty' (IN03).
Regulatory and Payer Landscape Influences All Horizons
The evolving regulatory landscape (IN04) and increasing payer scrutiny (MD03) influence strategies across all horizons. H1 strategies must navigate pricing pressures, H2 development needs to consider market access and reimbursement from the outset, and H3 innovations face entirely new regulatory pathways and value-based pricing models.
Prioritized actions for this industry
Formalize Horizon-Specific Strategy and Governance
Establish distinct strategic objectives, key performance indicators (KPIs), and governance structures for each horizon. This ensures dedicated focus and resource allocation without cannibalizing or neglecting other horizons, directly addressing the challenge of balancing funding and attention across different timelines.
Implement Robust Lifecycle Management for Horizon 1 Products
Proactively plan and execute strategies for existing products, including patent extension through new formulations or delivery methods, indication expansion, and cost optimization. This mitigates the impact of 'Maintaining Revenue Growth Post-Patent Expiry' (MD01) and ensures stable cash flow to fund H2 and H3.
Cultivate External Innovation Ecosystem for Horizon 2 & 3
Actively engage with academic institutions, biotech startups, and venture capital firms through partnerships, licensing deals, and corporate venture funds. This provides access to novel science, technologies, and talent for H2 and H3, de-risking 'High R&D Investment and Failure Rates' (IN01) and accelerating pipeline development.
Develop a Dedicated Horizon 3 'Venture' Unit with Long-Term Focus
Create an independent unit, shielded from short-term financial pressures, specifically tasked with exploring and incubating disruptive technologies and business models. This unit should have different metrics and timelines, fostering true innovation without being constrained by traditional pharmaceutical development cycles, addressing 'Managing High R&D Risk and Uncertainty' (IN03) and 'High Financial Risk & Capital Intensive' (IN05).
From quick wins to long-term transformation
- Conduct an inventory and categorize all current R&D projects and existing products into the three horizons.
- Formalize a 'patent cliff' mitigation plan for top-selling H1 drugs, identifying potential new indications or formulations.
- Allocate a small, dedicated budget for 'exploratory' H3 projects, outside of the traditional R&D pipeline.
- Establish distinct leadership and teams responsible for each horizon, with tailored KPIs and reporting structures.
- Develop a structured process for scouting H2 acquisition targets and H3 partnership opportunities in emerging therapeutic areas.
- Integrate market access and reimbursement strategies early into H2 clinical development plans.
- Implement a dynamic portfolio management system that allows for flexible resource allocation and rebalancing across horizons based on evolving market and scientific insights.
- Foster a culture that embraces both incremental improvements (H1) and radical innovation (H3), with appropriate incentives and recognition.
- Leverage digital tools (e.g., AI-driven foresight) to continuously monitor the external environment for H2/H3 opportunities and threats.
- Insufficient funding or strategic attention to H2 and H3, leading to a depleted future pipeline.
- Applying H1 metrics (e.g., short-term ROI) to H2 or H3 initiatives, stifling true innovation.
- Lack of clear boundaries and communication between horizon teams, leading to conflict or duplication of effort.
- Failure to disinvest from underperforming H1 assets or H2 projects, tying up valuable resources.
- Organizational resistance to change, particularly in adopting new business models or technologies associated with H3.
Measuring strategic progress
| Metric | Description | Target Benchmark |
|---|---|---|
| Horizon 1 Revenue Retention Rate | Percentage of revenue maintained for H1 products post-patent expiry or against generic competition. | Achieve >80% retention after 3 years post-expiry |
| Horizon 2 Pipeline Advancement Rate | Number of drug candidates successfully progressing from preclinical to Phase I, Phase II, and Phase III clinical trials. | Increase successful progression by 5-10% annually |
| Horizon 3 Investment as % of Total R&D Budget | Percentage of the total R&D budget allocated to truly disruptive, long-term innovation projects and venture investments. | Maintain 10-15% of R&D budget |
| Number of New Therapeutic Area Entries (H2/H3) | Count of successful entries into new disease areas or modalities, demonstrating portfolio diversification. | 1-2 new entries every 3-5 years |
| Innovation Option Value (H3) | Assessment of potential future value from H3 projects, even if not yet commercial, based on scientific breakthroughs or market potential. | Track portfolio of H3 options with increasing valuation |
Other strategy analyses for Manufacture of pharmaceuticals, medicinal chemical and botanical products
Also see: Three Horizons Framework Framework